Sibaud V, Dalenc F, Chevreau C et al (2011) HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome. Oncologist 16:1469–1478

Article  PubMed  PubMed Central  Google Scholar 

Grothey A, Sobrero AF, Shields AF et al (2018) Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 378:1177–1188

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamazaki K, Yamanaka T, Shiozawa M et al (2021) Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial. Ann Oncol 32:77–84

Article  CAS  PubMed  Google Scholar 

Hamaguchi T, Shimada Y, Mizusawa J et al (2018) Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. Lancet Gastroenterol Hepatol 3:47–56

Article  PubMed  Google Scholar 

Masuda N, Lee SJ, Ohtani S et al (2017) Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 376:2147–2159

Article  CAS  PubMed  Google Scholar 

Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

Article  CAS  PubMed  Google Scholar 

Blum JL, Dieras V, Lo Russo PM et al (2001) Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759–1768

Article  CAS  PubMed  Google Scholar 

Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697

Article  CAS  PubMed  Google Scholar 

Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46

Article  CAS  PubMed  Google Scholar 

Yamaguchi K, Sawaki A, Doi T et al (2013) Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study. Gastric Cancer 16:175–182

Article  CAS  PubMed  Google Scholar 

Yokokawa T, Kawakami K, Mae Y et al (2015) Risk factors exacerbating hand-foot skin reaction induced by capecitabine plus oxaliplatin with or without bevacizumab therapy. Ann Pharmacother 49:1120–1124

Article  CAS  PubMed  Google Scholar 

Leicher LW, de Graaf JC, Coers W et al (2017) Tolerability of capecitabine monotherapy in metastatic colorectal cancer: A real-world study. Drugs R D 17:117–124

Article  CAS  PubMed  Google Scholar 

Lakkunarajah S, Breadner DA, Zhang H et al (2021) The influence of adjuvant chemotherapy dose intensity on five-year outcomes in resected colon cancer: a single centre retrospective analysis. Curr Oncol 28:4031–4041

Article  PubMed  PubMed Central  Google Scholar 

Scheithauer W, Blum J (2004) Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park) 18:1161–1168

PubMed  Google Scholar 

Degen A, Alter M, Schenck F et al (2010) The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges 8:652–661

PubMed  Google Scholar 

Hofheinz RD, Gencer D, Schulz H et al (2015) Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: A randomized phase III trial of the AIO quality of life working group. J Clin Oncol 33:2444–2449

Article  CAS  PubMed  Google Scholar 

Wolf SL, Qin R, Menon SP et al (2010) Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5. J Clin Oncol 28:5182–5187

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu W, Huang Z, Chen S et al (2021) The effectiveness of EVOSKIN®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial. Ann Palliat Med 10:3009–3017

Article  PubMed  Google Scholar 

Zhang RX, Wu XJ, Lu SX et al (2011) The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study. J Cancer Res Clin Oncol 137:953–957

Article  CAS  PubMed  Google Scholar 

Zhang RX, Wu XJ, Wan DS et al (2012) Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 23:1348–1353

Article  CAS  PubMed  Google Scholar 

Yamamoto D, Yamamoto C, Iwase S et al (2010) Efficacy of vitamin E treatment for hand-foot syndrome in patients receiving capecitabine. Breast Care (Basel) 5:415–416

Article  PubMed  Google Scholar 

Jo SJ, Shin H, Jo S et al (2015) Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis. Clin Exp Dermatol 40:260–270

Article  CAS  PubMed  Google Scholar 

Son HS, Lee WY, Lee WS et al (2009) Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Yonsei Med J 50:796–802

Article  PubMed  PubMed Central  Google Scholar 

Van Cutsem E, Twelves C, Cassidy J et al (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19:4097–4106

Article  PubMed  Google Scholar 

Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485–493

Article  CAS  PubMed  Google Scholar 

Lacouture ME, Sibaud V, Gerber PA et al (2021) Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines(☆). Ann Oncol 32:157–170

Article  CAS  PubMed  Google Scholar 

Diasio RB (2000) Oral DPD-inhibitory fluoropyrimidine drugs. Oncology (Williston Park) 14:19–23

CAS  PubMed  Google Scholar 

Yokomichi N, Nagasawa T, Coler-Reilly A et al (2013) Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin. Hum Cell 26:8–18

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iimura Y, Furukawa N, Ishibashi M et al (2022) Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study). BMC Gastroenterol 22:341

Article  CAS  PubMed  PubMed Central  Google Scholar 

Santhosh A, Kumar A, Pramanik R et al (2022) Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study). Trials 23:420

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drake RD, Lin WM, King M et al (2004) Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol 94:320–324

Article  CAS  PubMed